Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIONASDAQ:BEAMNASDAQ:RVMDNASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$33.10-0.7%$34.47$21.62▼$39.54$6.29B1.152.44 million shs1.57 million shsBEAMBeam Therapeutics$17.03+1.2%$18.17$13.53▼$35.25$1.71B2.351.45 million shs1.33 million shsRVMDRevolution Medicines$36.97-7.0%$37.54$29.17▼$62.40$6.89B1.111.50 million shs3.76 million shsTGTXTG Therapeutics$35.24+1.9%$37.84$15.16▼$46.48$5.59B2.212.98 million shs1.29 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.72%-1.81%-8.84%-1.05%+18.47%BEAMBeam Therapeutics+1.19%-4.06%-12.76%-38.94%-29.98%RVMDRevolution Medicines-7.04%-8.65%-4.64%-8.72%-2.58%TGTXTG Therapeutics+1.94%-0.65%-14.74%+20.11%+110.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.5073 of 5 stars4.52.00.03.92.23.30.6BEAMBeam Therapeutics3.2697 of 5 stars4.51.00.00.03.62.50.6RVMDRevolution Medicines4.4064 of 5 stars4.51.00.04.73.62.50.0TGTXTG Therapeutics3.8098 of 5 stars2.42.00.03.53.61.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.92Moderate Buy$57.0972.48% UpsideBEAMBeam Therapeutics 3.00Buy$48.75186.26% UpsideRVMDRevolution Medicines 3.00Buy$67.0881.45% UpsideTGTXTG Therapeutics 2.80Moderate Buy$40.8015.78% UpsideCurrent Analyst Ratings BreakdownLatest BEAM, RVMD, BBIO, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.005/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.005/7/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.004/30/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.004/30/2025BBIOBridgeBio PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.004/30/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $72.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$127.42M49.33N/AN/A($7.71) per share-4.29BEAMBeam Therapeutics$63.58M26.94N/AN/A$12.04 per share1.41RVMDRevolution Medicines$742K9,280.77N/AN/A$11.09 per share3.33TGTXTG Therapeutics$386.39M14.48$0.10 per share353.90$1.06 per share33.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-241.44%N/A-75.69%8/7/2025 (Estimated)BEAMBeam Therapeutics-$132.53M-$4.61N/AN/AN/A-41.07%-16.22%-10.94%8/5/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)TGTXTG Therapeutics$12.67M$0.24N/A35.24N/A-5.42%-8.32%-3.40%8/5/2025 (Estimated)Latest BEAM, RVMD, BBIO, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million3/3/2025Q4 2024TGTXTG Therapeutics$0.08$0.15+$0.07$0.15$100.67 million$108.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ABEAMBeam Therapeutics$0.905.28%N/AN/A N/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.674.67BEAMBeam TherapeuticsN/A5.695.69RVMDRevolution MedicinesN/A14.2414.24TGTXTG Therapeutics1.274.593.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%BEAMBeam Therapeutics99.68%RVMDRevolution Medicines94.34%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%BEAMBeam Therapeutics4.20%RVMDRevolution Medicines8.20%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million143.29 millionOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableRVMDRevolution Medicines250186.27 million154.76 millionOptionableTGTXTG Therapeutics290158.76 million139.32 millionOptionableBEAM, RVMD, BBIO, and TGTX HeadlinesRecent News About These CompaniesTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual MeetingMay 27 at 7:30 AM | globenewswire.comConnecticut Wealth Management LLC Sells 13,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)May 25 at 5:53 AM | marketbeat.comTwo Sigma Investments LP Trims Position in TG Therapeutics, Inc. (NASDAQ:TGTX)May 25 at 4:23 AM | marketbeat.comProShare Advisors LLC Acquires 12,951 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)May 25 at 4:04 AM | marketbeat.comCaptrust Financial Advisors Sells 22,765 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)May 24, 2025 | marketbeat.comCastleark Management LLC Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)May 23, 2025 | marketbeat.comDeutsche Bank AG Has $4.43 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Has $80.71 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)May 21, 2025 | marketbeat.comWexford Capital LP Invests $421,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)May 21, 2025 | marketbeat.comNuveen Asset Management LLC Has $54.15 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)May 21, 2025 | marketbeat.comBalyasny Asset Management L.P. Invests $274,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)May 20, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial MarketsMay 20, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 20, 2025 | marketbeat.comRafferty Asset Management LLC Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)May 19, 2025 | marketbeat.comGotham Asset Management LLC Sells 64,333 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)May 19, 2025 | marketbeat.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or TG Therapeutics, Inc. Stock?May 18, 2025 | aaii.comJacobs Levy Equity Management Inc. Has $2.55 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)May 18, 2025 | marketbeat.comNicholas Investment Partners LP Reduces Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)May 16, 2025 | marketbeat.comJ. Goldman & Co LP Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)May 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Purchases Shares of 150,000 TG Therapeutics, Inc. (NASDAQ:TGTX)May 14, 2025 | marketbeat.comBrevan Howard Capital Management LP Takes $453,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)May 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBEAM, RVMD, BBIO, and TGTX Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$33.10 -0.24 (-0.72%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$32.57 -0.53 (-1.61%) As of 05/27/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Beam Therapeutics NASDAQ:BEAM$17.03 +0.20 (+1.19%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$17.05 +0.02 (+0.12%) As of 05/27/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Revolution Medicines NASDAQ:RVMD$36.97 -2.80 (-7.04%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$37.58 +0.62 (+1.66%) As of 05/27/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.TG Therapeutics NASDAQ:TGTX$35.24 +0.67 (+1.94%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$35.06 -0.18 (-0.50%) As of 05/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
